webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Eribulin Mesylate

  CAS No.: 441045-17-6   Cat No.: BADC-01399   Purity: ≥95% 4.5  

Eribulin Mesylate is an antitumor drug that can be used to treat patients with metastatic breast cancer. It inhibits the proliferation of cancer cells by binding tubulin and microtubules. Eribulin Mesylate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Eribulin Mesylate

Structure of 441045-17-6

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C41H63NO14S
Molecular Weight
826.01

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
1 mg $1099 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (1:1); 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt); E 7389 methanesulfonate; Halaven; Eribulin monomethanesulfonate
IUPAC Name
(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid
Canonical SMILES
CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O
InChI
InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1
InChIKey
QAMYWGZHLCQOOJ-WRNBYXCMSA-N
Solubility
Soluble in DMSO
Appearance
Powder
Quality Standard
-
Current Developer
Eisai
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT00047034E7389 in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificPhase 1August 2002National Cancer Institute (NCI)Completed
NCT00334893Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerFallopian Tube CancerPhase 2April 2006National Cancer Institute (NCI)Completed
NCT00337077Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyAdenocarcinoma of the ProstatePhase 2November 2006National Cancer Institute (NCI)Completed
NCT00337103E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesMetastatic Breast CancerPhase 3June 15, 2006Eisai Inc.Completed
NCT00337129S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck CancerHead and Neck CancerPhase 2May 2006National Cancer Institute (NCI)Completed

Eribulin Mesylate is a synthetic analog of halichondrin B and a potent ADC cytotoxin explored as an ADC payload in antibody-drug conjugates. It functions as a microtubule dynamics inhibitor, binding to the plus ends of microtubules and preventing their elongation, which leads to mitotic arrest and subsequent apoptosis. Its unique mechanism of action makes it an effective cytotoxic agent for targeted cancer therapies.

Within antibody-drug conjugates, Eribulin Mesylate can be conjugated to monoclonal antibodies using cleavable or non-cleavable linker strategies. These linkers ensure that the payload remains inactive in systemic circulation and is only released within tumor cells after internalization and enzymatic processing. This targeted release enhances the antitumor efficacy of ADCs while minimizing systemic toxicity, making Eribulin Mesylate a reliable payload for precision oncology applications.

Applications of Eribulin Mesylate include its integration into experimental ADCs targeting both solid tumors and hematologic malignancies, such as breast cancer, lung cancer, and sarcomas. Its high cytotoxic potency allows effective antitumor activity even at low drug-to-antibody ratios (DARs). Additionally, Eribulin Mesylate’s structural features support conjugation with diverse linker chemistries, optimizing stability, intracellular release, and overall performance in next-generation ADC development programs.

1.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K1, Saito T2, Okubo K3, Kimizuka K4, Yamada H5, Sakurai T6, Ishizuna K7, Hata S8, Kai T9, Kurosumi M10. Breast Cancer Res Treat. 2016 Apr 28. [Epub ahead of print]
No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective clinical study in patients with metastatic breast cancer (MBC) who had well-defined taxane resistance. The present Phase II, multicenter, single-arm, open-label study aimed to obtain the evidence. Japanese female patients, aged 33-74 years who had the metastasis of taxane-resistant and histopathologically confirmed breast cancer, received eribulin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as free base]) as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle. The primary endpoint was the clinical benefit rate (CBR) [complete response (CR), partial response (PR), and long-term stable disease (LSD) ≥24 weeks]. A total of 51 patients underwent chemotherapy cycles (median 4; range 1-42 cycles). The CBR was 39.2 % (CR 2.0 %; PR 23.5 %; and LSD 13.7 %), and the rate of progressive disease was 49.0 %.
2.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K1, Saito T2, Okubo K3, Kimizuka K4, Yamada H5, Sakurai T6, Ishizuna K7, Hata S8, Kai T9, Kurosumi M10. Breast Cancer Res Treat. 2016 Apr 28. [Epub ahead of print]
No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective clinical study in patients with metastatic breast cancer (MBC) who had well-defined taxane resistance. The present Phase II, multicenter, single-arm, open-label study aimed to obtain the evidence. Japanese female patients, aged 33-74 years who had the metastasis of taxane-resistant and histopathologically confirmed breast cancer, received eribulin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as free base]) as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle. The primary endpoint was the clinical benefit rate (CBR) [complete response (CR), partial response (PR), and long-term stable disease (LSD) ≥24 weeks]. A total of 51 patients underwent chemotherapy cycles (median 4; range 1-42 cycles). The CBR was 39.2 % (CR 2.0 %; PR 23.5 %; and LSD 13.7 %), and the rate of progressive disease was 49.0 %.
3.Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S1, Asano M1, Adachi Y1, Matsui J2. Anticancer Res. 2016 Apr;36(4):1553-61.
BACKGROUND: Eribulin mesilate (eribulin), a first-in-class halichondrin B-based microtubule dynamics inhibitor, has been shown to promote vascular remodeling and reversal of epithelial-mesenchymal transition (EMT) apart from its antimitotic activity in breast cancer models.
4.Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P1, Polastro L2, Ameye L3, Jungels C2, Vakili J2, Paesmans M3, van den Eerenbeemt J2, Buttice A2, Gombos A2, de Valeriola D2, Gil T2, Piccart-Gebhart M2, Awada A2. Eur J Cancer. 2016 Apr 20;60:117-124. doi: 10.1016/j.ejca.2016.03.010. [Epub ahead of print]
BACKGROUND: Eribulin is a non-taxane microtubule dynamics inhibitor that showed a survival benefit versus treatment of physician's choice in a phase III trial enrolling patients with metastatic breast cancer (MBC).

What is Eribulin Mesylate?

Eribulin Mesylate is a synthetic microtubule dynamics inhibitor derived from halichondrin B. It interferes with tubulin polymerization, leading to mitotic blockage and apoptosis, and is utilized as a potent payload in ADC research for selective cytotoxic delivery.

2/7/2018

We would like to know how Eribulin Mesylate is used in ADC development.

Eribulin Mesylate serves as a cytotoxic payload in ADCs. It is conjugated to monoclonal antibodies targeting specific antigens, ensuring selective uptake by target cells and induction of apoptosis, while reducing systemic toxicity.

17/2/2018

Dear BOC Sciences, which linkers are suitable for Eribulin Mesylate ADCs?

Eribulin Mesylate can be coupled using cleavable linkers for intracellular release upon target cell internalization, or non-cleavable linkers to enhance stability in circulation. Linker selection affects pharmacokinetics and payload delivery efficiency.

28/8/2019

Dear Sir, may I ask what laboratory precautions are necessary when handling Eribulin Mesylate?

Due to its high cytotoxicity, Eribulin Mesylate must be handled with PPE, biosafety cabinets, and adherence to institutional safety guidelines. Proper waste disposal and containment are required to prevent accidental exposure during conjugation or experiments.

1/3/2019

Good morning! What advantages do Eribulin Mesylate ADCs provide in research applications?

Eribulin Mesylate ADCs allow targeted delivery of cytotoxic agents to cells expressing specific antigens. This improves therapeutic index, supports precision oncology research, and facilitates evaluation of novel ADC constructs in preclinical studies.

10/12/2022

— Dr. Jason Carter, Senior Scientist (USA)

Eribulin Mesylate from BOC Sciences showed high purity and excellent batch reproducibility.

28/8/2019

— Dr. Andrew Collins, Pharmaceutical Researcher (UK)

Eribulin Mesylate from BOC Sciences arrived on time and in excellent condition. It demonstrated consistent performance in our preclinical conjugation trials, reflecting reliable sourcing standards.

10/12/2022

— Dr. Markus Klein, Medicinal Chemist (Germany)

Fast delivery and detailed QC documentation for Eribulin Mesylate met all expectations.

1/3/2019

— Dr. Rebecca Shaw, Oncology Researcher (USA)

Our lab has tested Eribulin Mesylate from various vendors, but BOC Sciences provided the most reliable batch. Its solubility and purity supported efficient conjugation work with minimal troubleshooting.

2/7/2018

— Dr. William Adams, Lead Scientist (USA)

High-quality Eribulin Mesylate and responsive support. Perfect for our pipeline.

— Dr. Peter Hughes, Senior Chemist (UK)

Eribulin Mesylate from BOC Sciences was exceptionally consistent between batches. The compound’s stability allowed us to run prolonged conjugation studies without performance drift.

17/2/2018

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Mal-PEG2-acid | PNU159682-EDA | MC-VC-PAB-DMEA-PNU159682 | DMEA-PNU-159682 | DBCO-PEG4-VC-PAB-DMEA-PNU159682 | PNU-159682 carboxylic acid | Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 | Mal-PEG6-NHS ester | NHS-SS-Ph | sulfo-SPDB-DM4 | Eribulin Mesylate
Send Inquiry
Verification code
Inquiry Basket